Here's how we can make clinical trials more inclusive

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings1 for just about all forms of cancer. While screening rates rebounded in the fall of 20202, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone. And the data are compelling. From September to December 2020, for example, fewer Black and Hispanic women2 had mammograms than in the three months prior to the pandemic. In addition, Black men were 25% less likely3 than their white counterparts to get a prostatectomy during the pandemic. 

For the full article, please visit The Cancer Letter.